Swiss National Bank Has $2.28 Million Stake in CG Oncology, Inc. (NASDAQ:CGON)

Swiss National Bank increased its position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 144.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 79,600 shares of the company's stock after acquiring an additional 47,000 shares during the quarter. Swiss National Bank owned about 0.10% of CG Oncology worth $2,283,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. State Street Corp grew its holdings in CG Oncology by 73.0% during the 3rd quarter. State Street Corp now owns 1,700,653 shares of the company's stock worth $64,166,000 after acquiring an additional 717,722 shares during the period. Janus Henderson Group PLC lifted its stake in shares of CG Oncology by 7.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,526,534 shares of the company's stock valued at $57,596,000 after purchasing an additional 99,517 shares during the period. Franklin Resources Inc. boosted its position in shares of CG Oncology by 8.9% in the 3rd quarter. Franklin Resources Inc. now owns 1,230,193 shares of the company's stock worth $46,157,000 after purchasing an additional 100,106 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of CG Oncology by 96.2% during the third quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company's stock worth $40,701,000 after purchasing an additional 528,749 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in CG Oncology by 575.7% in the third quarter. Point72 Asset Management L.P. now owns 746,063 shares of the company's stock valued at $28,149,000 after purchasing an additional 635,653 shares during the last quarter. Institutional investors own 26.56% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

CGON has been the topic of a number of recent analyst reports. Royal Bank of Canada restated an "outperform" rating and set a $66.00 target price on shares of CG Oncology in a report on Friday, December 6th. HC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a research note on Monday. TD Cowen assumed coverage on shares of CG Oncology in a report on Tuesday, January 7th. They set a "buy" rating for the company. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $55.00 target price on shares of CG Oncology in a report on Friday, March 7th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $63.88.

Insider Transactions at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

CG Oncology Price Performance

CGON traded down $1.93 during trading on Monday, reaching $24.49. The company had a trading volume of 1,260,448 shares, compared to its average volume of 653,646. The company has a market cap of $1.86 billion, a P/E ratio of -17.25 and a beta of 1.60. CG Oncology, Inc. has a 12 month low of $23.91 and a 12 month high of $46.99. The business's fifty day moving average price is $27.82 and its 200 day moving average price is $31.72.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.11). The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.11 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. As a group, sell-side analysts predict that CG Oncology, Inc. will post -1.31 EPS for the current fiscal year.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.